Skip to main content

Closed

NVO: Novo Nordisk A/S Stock Analysis | finqOS

Healthcare · Drug Manufacturers - General

Loading chart data...

Current StateBalance holding

The verdict

Good business

Strong

Revenue growth+25.0% / yr

Operating margin45.3%

ROIC32.2%

Financially safe

Strong

Debt / equity0.72×

Interest coverage29.1×

Current ratio0.79×

Valuation

Unrated

P/E ratio11.2×

Dividend yield3.8%

Novo Nordisk A/S

NVONew York Stock Exchange·USD·Closed

Novo Nordisk A/S

NVONew York Stock Exchange·USD·Closed

$47.08

−8.79%

$47.08

−$4.53 (8.79%)

52W Range

41thpctl

Volume

2.01×avg

Mkt Cap

209.19BUSD

P/E

11.2TTM

Div Yield

3.82%ann

52W Range

41thpctl

Volume

2.01×avg

Market Cap

209.19BUSD

P/E Ratio

11.2TTM

Div Yield

3.82%ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings